Cleared Traditional

K884169 - DU PONT ANALYST THYROID ROTOR (FDA 510(k) Clearance)

Class I Chemistry device.

K884169 · The DU Pont Co. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1989
Decision
112d
Days
Class 1
Risk

K884169 is an FDA 510(k) clearance for the DU PONT ANALYST THYROID ROTOR. Classified as Ammonium Molybdate And Ammonium Vanadate, Phospholipids (product code CEL), Class I - General Controls.

Submitted by The DU Pont Co. (Wilmington, US). The FDA issued a Cleared decision on January 24, 1989 after a review of 112 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1575 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all The DU Pont Co. devices

Submission Details

510(k) Number K884169 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 04, 1988
Decision Date January 24, 1989
Days to Decision 112 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
24d slower than avg
Panel avg: 88d · This submission: 112d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code CEL Ammonium Molybdate And Ammonium Vanadate, Phospholipids
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1575
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.